Kallikrein-kinin in stem cell therapy

doi:10.4252/wjsc.v6.i4.448

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 4

This Article

(351)

(269)

(0)

(8035)

(10)

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Stem Cells. Sep 26, 2014; 6(4): 448-457
Published online Sep 26, 2014. doi: 10.4252/wjsc.v6.i4.448

Table 1 Enhanced protection by stem cells genetically modified with tissue kallikrein

	Apoptosis	Inflammation	Oxidative stress	Tissue remodeling	Angiogenesis
TK-MSCs
Renal I/R[66]	↓	↓	↓	--	--
Lupus nephritis[74]	↓	↓	↓	--	--
MI[67]	↓	↓	--	↓	↑
TK-EPCs
MI[87]	↓	--	↓	--	↑
Limb ischemia[88]	--	--	--	--	↑

TK-MSCs: Tissue kallikrein-modified mesenchymal stem cells; I/R: Ischemia/reperfusion; MI: Myocardial infarction; TK-EPCs: Tissue kallikrein-modified endothelial progenitor cells.

Full Size Table

Citation: Chao J, Bledsoe G, Chao L. Kallikrein-kinin in stem cell therapy. World J Stem Cells 2014; 6(4): 448-457
URL: https://www.wjgnet.com/1948-0210/full/v6/i4/448.htm
DOI: https://dx.doi.org/10.4252/wjsc.v6.i4.448

Chao J, Bledsoe G, Chao L. Kallikrein-kinin in stem cell therapy. World J Stem Cells 2014; 6(4): 448-457 [PMID: 25258666 DOI: 10.4252/wjsc.v6.i4.448]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.